• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺小细胞癌与大细胞神经内分泌癌的观察者间变异性。

Small cell carcinoma of the lung and large cell neuroendocrine carcinoma interobserver variability.

机构信息

Department of Pathology, Erasmus MC, PO Box 2040, 3000 CA, Rotterdam, the Netherlands.

出版信息

Histopathology. 2010 Feb;56(3):356-63. doi: 10.1111/j.1365-2559.2010.03486.x.

DOI:10.1111/j.1365-2559.2010.03486.x
PMID:20459535
Abstract

AIMS

To test the hypothesis that the published morphological criteria permit reliable segregation of small cell carcinoma of the lung (SCLC) and large cell neuroendocrine carcinoma (LCNEC) cases by determining the interobserver variation.

METHODS AND RESULTS

One hundred and seventy cases of SCLC, LCNEC and cases diagnosed as neuroendocrine lung carcinoma before LCNEC had been established as a diagnostic category were retrieved from the archives of the assessor's institutes. A representative haematoxylin and eosin section from each case was selected for review. Batches of cases were circulated among nine pathologists with a special interest in pulmonary pathology. Participants were asked to classify the cases histologically according to the 2004 World Health Organization (WHO) criteria. The diagnoses were collected and kappa values calculated. Unanimity of diagnosis was achieved for only 20 cases; a majority diagnosis was reached for 115 cases. In 35 cases no consensus diagnosis could be reached. There was striking variability amongst assessors in diagnosing SCLC and LCNEC. The overall level of agreement for all cases included in this study was fair (kappa=0.40).

CONCLUSIONS

Using non-preselected cases, the morphological WHO criteria for diagnosing SCLC and LCNEC leave room for subjective pathological interpretation, which results in imprecise categorization of SCLC and LCNEC cases.

摘要

目的

通过确定观察者间的变异来检验发表的形态学标准是否能够可靠地区分小细胞肺癌(SCLC)和大细胞神经内分泌癌(LCNEC)的假设。

方法和结果

从评估机构的档案中检索了 170 例 SCLC、LCNEC 和在 LCNEC 被确立为诊断类别之前被诊断为神经内分泌肺癌的病例。从每个病例中选择一个有代表性的苏木精和伊红切片进行审查。将病例分批分发给 9 位对肺部病理学有特殊兴趣的病理学家。要求参与者根据 2004 年世界卫生组织(WHO)标准对病例进行组织学分类。收集诊断并计算kappa 值。只有 20 例达到一致诊断;115 例达到多数诊断。在 35 例中,无法达成共识诊断。在诊断 SCLC 和 LCNEC 方面,评估者之间存在显著的差异。包括在本研究中的所有病例的总体一致性水平为中等(kappa=0.40)。

结论

使用非预选病例,用于诊断 SCLC 和 LCNEC 的形态学 WHO 标准存在主观病理解释的空间,这导致 SCLC 和 LCNEC 病例的分类不准确。

相似文献

1
Small cell carcinoma of the lung and large cell neuroendocrine carcinoma interobserver variability.肺小细胞癌与大细胞神经内分泌癌的观察者间变异性。
Histopathology. 2010 Feb;56(3):356-63. doi: 10.1111/j.1365-2559.2010.03486.x.
2
Pulmonary large cell neuroendocrine carcinoma: its place in the spectrum of pulmonary carcinoma.肺大细胞神经内分泌癌:其在肺癌谱系中的地位。
Ann Thorac Surg. 2007 Aug;84(2):702-7. doi: 10.1016/j.athoracsur.2007.03.093.
3
High-grade neuroendocrine carcinoma of the lung: comparative clinicopathological study of large cell neuroendocrine carcinoma and small cell lung carcinoma.肺高级别神经内分泌癌:大细胞神经内分泌癌与小细胞肺癌的临床病理对照研究
Pathol Int. 2009 Aug;59(8):522-9. doi: 10.1111/j.1440-1827.2009.02402.x.
4
A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma.肺外周、小细胞型高级神经内分泌肿瘤的临床病理研究:小细胞肺癌与大细胞神经内分泌癌的区别。
Eur J Cardiothorac Surg. 2012 Apr;41(4):841-6. doi: 10.1093/ejcts/ezr132. Epub 2011 Dec 21.
5
Immunohistochemical differential diagnosis between large cell neuroendocrine carcinoma and small cell carcinoma by tissue microarray analysis with a large antibody panel.通过组织微阵列分析和大量抗体组进行大细胞神经内分泌癌与小细胞癌的免疫组化鉴别诊断。
Am J Clin Pathol. 2006 May;125(5):682-92. doi: 10.1309/DT6B-J698-LDX2-NGGX.
6
Reproducibility of neuroendocrine lung tumor classification.神经内分泌性肺肿瘤分类的可重复性。
Hum Pathol. 1998 Mar;29(3):272-9. doi: 10.1016/s0046-8177(98)90047-8.
7
Genetic alterations in early-stage pulmonary large cell neuroendocrine carcinoma.早期肺大细胞神经内分泌癌的基因改变
Cancer. 2004 Mar 15;100(6):1190-8. doi: 10.1002/cncr.20108.
8
Anti-HuC and -HuD autoantibodies are differential sero-diagnostic markers for small cell carcinoma from large cell neuroendocrine carcinoma of the lung.抗 HuC 和 HuD 自身抗体是鉴别诊断小细胞肺癌和肺大细胞神经内分泌癌的血清学标志物。
Int J Oncol. 2012 Jun;40(6):1957-62. doi: 10.3892/ijo.2012.1405. Epub 2012 Mar 16.
9
Characteristics of loss of heterozygosity in large cell neuroendocrine carcinomas of the lung and small cell lung carcinomas.肺大细胞神经内分泌癌和小细胞肺癌中杂合性缺失的特征
Pathol Int. 2006 Aug;56(8):434-9. doi: 10.1111/j.1440-1827.2006.01985.x.
10
Chromosomal aberrations in a series of large-cell neuroendocrine carcinomas: unexpected divergence from small-cell carcinoma of the lung.一系列大细胞神经内分泌癌中的染色体畸变:与肺小细胞癌意外的差异。
Hum Pathol. 2001 Oct;32(10):1059-63. doi: 10.1053/hupa.2001.28248.

引用本文的文献

1
Clinical needs and pathology's answers in neuroendocrine neoplasms of the lung.肺部神经内分泌肿瘤的临床需求与病理学解答
Pathologica. 2025 Jun;117(3):220-242. doi: 10.32074/1591-951X-N1102. Epub 2025 Jun 27.
2
Neuroendocrine neoplasms of the lung: The latest updates.肺神经内分泌肿瘤:最新进展
World J Clin Oncol. 2025 May 24;16(5):106630. doi: 10.5306/wjco.v16.i5.106630.
3
Epigenetic Modifications as Novel Biomarkers for Diagnosis, Prognosis, and Therapeutic Targeting in Thyroid, Pancreas, and Lung Neuroendocrine Tumors.
表观遗传修饰作为甲状腺、胰腺和肺神经内分泌肿瘤诊断、预后及治疗靶点的新型生物标志物
J Clin Med. 2025 Apr 11;14(8):2622. doi: 10.3390/jcm14082622.
4
Case report: A patient with EGFR L861Q positive adenosquamous lung carcinoma transforming into large cell neuroendocrine cancer after treatment with Almonertinib.病例报告:一名表皮生长因子受体(EGFR)L861Q阳性腺鳞癌患者在接受阿美替尼治疗后转化为大细胞神经内分泌癌。
Front Oncol. 2025 Feb 18;15:1453066. doi: 10.3389/fonc.2025.1453066. eCollection 2025.
5
Clinical characteristics and treatment management of combined large cell neuroendocrine carcinoma, a subtype of large cell neuroendocrine carcinoma.大细胞神经内分泌癌的一种亚型——联合大细胞神经内分泌癌的临床特征及治疗管理
Front Oncol. 2024 Oct 22;14:1449490. doi: 10.3389/fonc.2024.1449490. eCollection 2024.
6
Diagnostic alignment to optimize inter-rater reliability among lung transplant pathologists.诊断一致性优化肺移植病理学家之间的评分者间可靠性。
J Heart Lung Transplant. 2025 Feb;44(2):173-181. doi: 10.1016/j.healun.2024.10.007. Epub 2024 Oct 13.
7
Advances in genetic profile and therapeutic strategy of pulmonary large cell neuroendocrine carcinoma.肺大细胞神经内分泌癌的基因特征及治疗策略进展
Front Med (Lausanne). 2024 Feb 27;11:1326426. doi: 10.3389/fmed.2024.1326426. eCollection 2024.
8
Risk factors associated with survival in surgically treated large cell neuroendocrine carcinoma of the lung.手术治疗的肺大细胞神经内分泌癌生存相关危险因素。
Kardiochir Torakochirurgia Pol. 2023 Mar;20(1):7-11. doi: 10.5114/kitp.2023.126092. Epub 2023 Apr 3.
9
Proposing Specific Neuronal Epithelial-to-Mesenchymal Transition Genes as an Ancillary Tool for Differential Diagnosis among Pulmonary Neuroendocrine Neoplasms.提出特定的神经元上皮-间充质转化基因作为肺神经内分泌肿瘤鉴别诊断的辅助工具。
Genes (Basel). 2022 Dec 7;13(12):2309. doi: 10.3390/genes13122309.
10
Pulmonary Large Cell Neuroendocrine Carcinoma.肺大细胞神经内分泌癌。
Pathol Oncol Res. 2022 Oct 11;28:1610730. doi: 10.3389/pore.2022.1610730. eCollection 2022.